ArticleBiology direct2026
Revealing FPR1 as a potential pathogenic biomarker for aortic dissection based on Mendelian randomization, single-cell transcriptome and clinical data analysis.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAortic dissection is characterized by immune cell infiltration and vascular inflammation, yet its molecular mechanisms remain unclear. This study investigates the role of immune-related genes in AD pathogenesis.
methodsWe integrated Mendelian randomization and transcriptomic analyses to identify AD-associated genetic risk genes. Immune infiltration and functional enrichment analyses were applied to explore monocyte and neutrophil involvement. Key genes were validated in human and mouse aortic tissues, and FPR1’s role was assessed using Cyclosporin H treatment. Clinical correlation between FPR1 expression and prognosis was evaluated.
resultsEight highly differentially expressed genes were identified, with FPR1 showing predominant expression in myeloid cells. Single-cell and bulk RNA-seq revealed immune cell accumulation in AD tissues, where FPR1 correlated with monocyte/neutrophil activation and enhanced vascular inflammation. FPR1 upregulation in AD tissues accompanied increased neutrophil activation markers (TNF-α, IL-1β, IL-6, CCL2). FPR1 inhibition suppressed ERK1/2 pathway activation, reduced IL-1β production, and attenuated AD severity in mice. Clinically, elevated FPR1 levels were associated with disease severity and predicted poor postoperative outcomes, with significantly higher expression in 30-day non-survivors.
conclusionFPR1 plays a critical role in AD pathogenesis by promoting myeloid immune cell activation and vascular inflammation, highlighting its potential as a therapeutic target and prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.